-- 長春ハイテク工業（SHE:000661）の子会社である長春遺伝子科製薬は、同社のモノクローナル抗体注射剤「福心七百（ふくしんきばび）」の製造・販売について、中国の規制当局の承認を取得した。 深セン証券取引所への木曜日の提出書類によると、この薬剤は、標準治療に反応しにくい成人の急性痛風性関節炎発作の治療薬として適応される。
Related Articles
Asia
Humanwell Healthcare Gets Clinical Trial Approval for Opioid Alternative
Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioidsShares of the pharmaceutical company declined 1% in recent trade.
$SHA:600079
Asia
Tibet Huayu Mining Shareholder to Divest 1% Stake in Company
A Tibet Huayu Mining (SHA:601020) shareholder plans to reduce part of its holdings to meet its own business development needs, according to a Shanghai bourse filing on Thursday.Qinghai Western Rare Precious Metals will offload 8,200,000 shares, or around 1% of the mining company's total shares, between May 29 and Aug. 28.Qinghai Western Rare Precious Metals currently owns 72,336,364 shares, or 8.8% of the company's total shares.
$SHA:601020
Asia
Taiwan Mask Mulls Private Placement of Up to 20 Million Shares; Shares Rally 10%
Taiwan Mask (TPE:2338) board approved a plan to privately place up to 20 million shares in one to three tranches within a year, according to a filing with the Taiwan Exchange on Wednesday.Shares of the photomask manufacturer jumped about 10% in Thursday's midday trade.Proceeds from the offering are earmarked for working capital, factory expansion, machinery and equipment procurement, debt repayment, and other long-term development needs.Potential subscribers may include insider and related parties such as Luminous Rise Investment, TrueLight Corp., Star Fusion Group, and ALi Corp. (TPE:3041), although no final placees have been selected, it said.
$TPE:2338